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Background: In November 2004, a national target was set for the English hospital trusts to reduce the
Meticillin-Resistant Staphylococcus aureus (MRSA) bacteremia rate by 60% by April 2008 against the number during
2003/04 (baseline year). In our organisation the number of MRSA bacteremias had risen since 2002 and peaked at
75 in 2005/06. A target was set to reduce the number and series of specific and non- specific interventions was
introduced including universal MRSA screening. This study analyzes the impact of universal MRSA screening using a
quasi-experimental design using routinely gathered data.
Methods: This study used data gathered routinely for clinical governance, quality control, financial management
and outbreak monitoring purposes. Interrupted Time Series (ITS) analysis of 15 pre- and 19 post- universal MRSA
screening (and decolonisation) quarterly numbers of bacteremias was carried out where Meticillin-Sensitive
Staphylococcus aureus (MSSA) numbers served as non-equivalent dependent variable (control).
Results: An immediate sharp fall in MRSA bacteremias was observed following the universal MRSA screening (and
decolonisation) commenced in Q2, 2007. The number dropped sharply from 23 (Q2, 2007) to 10 (Q3, 2007) for all
MRSA bacteremias, and, from 15 (Q2, 2007) to 6 (Q3, 2007) for bacteremias ≥48 hours of hospitalization. The
declining trend continued reaching zero in Q2, 2009 and Q4, 2010 for those with ≥48 hours of hospitalization and
all bacteremias, respectively. ITS analysis revealed significant impact of universal MRSA screening on all MRSA
bacteremias (β2 -0.554, p 0.000) and those with ≥48 of hospitalization (β2 -0.577, p 0.001). Impact estimation
predicted 17 and 13 bacteremias for all and those with ≥48 hours hospitalization, respectively in the 19th quarter
post-intervention, if the intervention did not occur. The number of MRSA isolates from non-blood culture systemic
sources as percentage of admissions also dropped significantly from 3.32% in Q2, 2007 to 1.51% in Q3, 2007
(β2 -0.506, p 0.000) which is still running low at 0.33% at the end of Q1, 2012. On the other hand, there was no
statistically significant impact of universal screening on MSSA bacteremias.
Conclusions: We conclude that of all interventions, the universal MRSA screening (and decolonisation) is the most
effective intervention associated with significant and sharp drop in MRSA burden.Background
In November 2004, a national target was set for the English
hospital trusts to reduce the Meticillin-Resistant Staphylo-
coccus aureus (MRSA) bacteremia rate by 60% by April
2008 against the number during 2003/04 (baseline year). In
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facilitated by Department of Health (DoH) in May 2006. A
series of specific- and non-specific interventions was intro-
duced since May 2006. The ‘Clean your hands’ campaign
was already ongoing since September 2004. This study
reviews the impact of these interventions to reduce the
burden of MRSA bacteremias, specifically, the impact of
universal MRSA screening using a quasi-experimental
(Interrupted Time Series - ITS) design using routinely
gathered data in the context of a comprehensive infection
control program.td. This is an Open Access article distributed under the terms of the Creative
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The setting is an acute NHS Trust in the north east of
England serving a mixed urban/rural predominantly eld-
erly population of approximately 500,000. The Trust has
three acute district general and seven community hospi-
tals with 760 acute medical/elderly care beds, and 183
acute surgical beds including orthopedics. The average
number of beds per ward is 21 with 82.9% bed occu-
pancy. There is an active infection control team (ICT)
with four point five whole time equivalent microbiolo-
gists, seven infection control nurses and input from
other specialties including pharmacy. The study used
no patient identifiable information and is a non-
interventional observational study and as such did not
require ethical approval.
Data collection
This study used data gathered routinely for clinical gov-
ernance, quality control, financial management and out-
break monitoring purposes. The numbers of monthly
bacteremias were routinely recorded for governance pur-
poses. The review of surveillance (Sept 2004 to March
2006) data showed the sources of MRSA bacteremias to
be unknown in an unusually large proportion (30%) of
cases, and in the rest, three major sources were identi-
fied viz., indwelling intra vascular devices, chest infec-
tions and soft tissue infections (Figure 1). Following the
introduction of Root Cause Analysis (RCA) in May 2006 a
number of interventions were made in quick succession
as part of the MRSA improvement programme; imple-
mentation of these interventions and compliance levels
were routinely monitored by audits (Table 1). Universal
MRSA Screening and Decolonization was introduced in





















Figure 1 Sources of bacteraemias: September 2006 to March 2007.selective based on certain risk factors including pre-
operative patients in elective surgery, emergency orthope-
dics and trauma surgery, critical care, patients known to
be MRSA positive, oncology/chemotherapy inpatients and
patients admitted from high-risk settings [1]. The hospi-
tals screened only about 1600 patients per quarter before
May, 2007. In May, 2007, the universal screening was
introduced in a phased manner to include all adult elect-
ive, day case and emergency admissions. This was imple-
mented in advance of the NHS Operating Framework for
the NHS in England 2008/09 [2] which required screening
for all elective admissions by April 2009 and all emergency
admissions no later than 2011.
Swabs were placed on to MRSA Select™ (Bio-Rad)
chromogenic agar medium and presumptive pink MRSA
colonies were confirmed by a latex slide test. Full bio-
chemical identification and antibiotic susceptibility were
carried out by The VITEKW 2 (bioMérieux UK) system.
All positive MRSA results were communicated directly
to the ICT. Average turnaround time was 48 hours.
The number of patients screened increased to 5000 in
Q2, 2007 reaching 15000 in Q1, 2009 which has
remained stable (Figure 2). A weekly MRSA screening
audit commenced in September, 2007 showed near 100%
screening compliance achieved by beginning of April,
2009 for all elective and emergency admissions.
The MRSA positive patients were isolated according
to the infection control policy and commenced on
decolonisation treatment as soon they were identified
irrespective of whether facilities were available to isolate.
OctenisanW (or 2% Triclosan) body wash once daily and
Mupirocin 2% Nasal ointment three times a day to the
inside of each nostril for 5 days (and hair washing with










Table 1 Timeline of infection control interventions since Sep 2004
Year Period Interventions Description (compliance/comments)
2004 Sep ‘Clean your hands’ campaign [3] Compliance (against opportunities available) 62-72% at baseline rising to
82% by April 2008. Intense daily monitoring continued with results
aggregated and compiled weekly until 95% compliance was achieved at
which point frequency was reduced to weekly. In most locations within a
few weeks the level of compliance rose to over 95%.
2006 May Root cause Analysis (RCA) The information capture tool was given to the clinical teams within hours of
the identification of MRSA bacteremia. Once received back by the ICT further
in depth investigation (if necessary) was carried out by the Infection Control
Nurses (ICN). The clinical teams are updated during the regular visits by
Microbiologists or ICNs. More formal feedback occurs during Clinical







Junior Doctor’s Induction Video
Sep Support Worker’s Training
Nov The peripheral vascular care (PVC) care
plan (High Impact Intervention [4])
Two one day audits in April 2007 and May 2007 showed improvement in
usage. Another audit commenced on 22nd October 2007 for 37 consecutive
weeks showed the number of cannula in situ for >72 hours was only a few
and improved compliance to other elements of the care plan viz., (1)
removal if no continued clinical indication, (2) use of care plan, (3) daily
visual assessment and (4) intact dressing was observed within a few weeks
and maintained throughout the period.
Dec
2007 May Universal Screening and decolonization See result section for full description. 100% compliance both for elective and
emergency admissions achieved by beginning April 2009.
The central vascular care (CVC) care plan
Weekly HCAI meeting A weekly HCAI meeting chaired by the Director of Infection Prevention and
Control has been held since May 2007 regularly attended by ICNs, consultant
Microbiologists, ward matrons, domestic manager and the director of
nursing among others. This group reviews three weekly audits carried out
regularly: MRSA screening, PVC care plan and hand hygiene audits in
addition to other infection control audits. Another daily meeting for
enhanced management of known MRSA positives patients was introduced
in March 2008. This group facilitates feedback of results to the relevant staff
and ensures that recommended measures are backed by support from high
level management in terms of resources.
Jul Improved blood culture technique (‘Taking blood
cultures: A summary of best practice’ (DoH, June 2007)
The blood culture policy was re-issued which required that indication was
recorded in the medical notes and blood culture was authorised by a
consultant/senior doctor. A training video was made available on the Trust
intranet to demonstrate how to take cultures using aseptic technique. This
was also shown at induction for new junior doctors. In June, the number of
blood cultures taken fell from the monthly average of 1252 to 778, a 38%
reduction, of which 16% were positive compared to 14.5% in the previous
five months. The proportion that was skin organisms (e.g., coagulase
negative staphylococci, diptheroids and propionibacterium) marginally
reduced to 24% from 29%.
Patient Administration System (PAS) MRSA alert Patients with previous MRSA history were tagged with an alert code on the
PAS to allow for decolonisation to commence within 24 hours of admission
in accordance with the MRSA policy.
Sep Standardised Intra Venous (IV) cannula site dressing
Universal screening compliance audit See above May, 2007.
Annual infection control study day and road show
Oct PVC care plan compliance audit See above November, 2006.
Web-based Audits Tool A web based data capture was introduced to audit MRSA screening,
peripheral cannula care and hand hygiene standards. This new system
enabled the ICT to produce weekly audit figures efficiently at review in the
weekly HCAI group meeting, identify the outliers and giving real-time feed
back to the ward staff to reinforce corrective measures and best practice in a
targeted and timely way.
ICN job description re-written to make duty and responsibility more explicit
2008 Jan NPSA screen saver on all hospital PCs
General Practitioner’s education on Infection Control
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Table 1 Timeline of infection control interventions since Sep 2004 (Continued)
New infection control ward entrance sign
Mar Management of screening positives Daily meeting for management of screening positives
MRSA Screening at day 10 Screening of all inpatients at day ten after admission (and then every ten
days).
Apr Hand hygiene audit See above Sep 2004 (‘Clean your hands’ campaign)
Aseptic training for the staff
June Junior doctor’s e-learning on Infection Control
Fluoroquinolone restriction Consumption dropped from average 12 Defined daily Dose (DDD)/100 bed-
days in previous 12 months to under 5 from June 2008 with a further drop
in consumption to under 2 from June 2010.
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for prompt prescribing of OctenisanW (or 2% Triclosan)
washes by the nursing staff was already in place. Patients
are re-screened 48 hours after completing decolonisation
if they are still in hospital. In general, up to two complete
courses of decolonisation were given during each in-
patient stay. Any patient who was still positive for MRSA
after a second decolonisation treatment received daily
washes using octenisan for the duration of their in-patient
stay.Analysis
For the interrupted time-series (ITS) analysis, we used
segmented linear regression, which divides a time series
into pre- and post-intervention segments. The universal
screening was introduced in Q2, 2007, therefore, Q3,
2007 was chosen as the intersection between the pre-
and post-intervention segments. Interventions that may
be short-lived may erroneously report maximal effects if
short time series are analyzed; our time series included







































Admission Patients No of Specimens Prevalence (%
Figure 2 Admissions, patients screened and specimen numbers (seco
axis) from Q1, 2007 to Q3, 2011 (Universal screening began in Q2, 20A linear regression model has two parameters: the
level and slope. Therefore the difference between the
two segments can be quantified by testing the change in
these two parameters (Equation 1). A change in level be-
tween the pre- and post-intervention segments indicates
a step-change, and a change in slope indicates a change
in trend.
Y t ¼ β0 þ β1T þ β2Dþ β3P ð1Þ
Yt
is the MRSA rate at month t;
β0
estimates the baseline MRSA quarterly rate;
β1
estimates the baseline (pre-intervention) linear
trend where T is a continuous variable indicating
the time in quarter interval at time t from the
start of the study period;
β2
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ndary axis) vs. on-admission colonisation prevalence (primary
07).
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and D = 1 after the intervention;
β3
estimates the mean quarterly trend in MRSA post-
intervention, compared to the baseline trend, where
P is a continuous variable indicating the number of
quarters after the start of the intervention at time
t and is coded as zero before the intervention.
Three points of interest were calculated: (1) pre-
intervention trend (slope); (2) post-intervention change
of the baseline level representing an immediate effect;
and (3) post-intervention trend (slope) representing a
sustained effect of the intervention. A p-value of 0.05
was regarded as statistically significant. If coefficient β1
was significantly different from 0, the pre-intervention
trend was deemed statistically significant. Similarly, if
β2 and/or β3 were significantly different from 0, it
was assumed that there had been a significant post-
intervention change of baseline level and/or trend.
We included Meticillin-Sensitive Staphylococcus aur-
eus (MSSA) numbers for the same period as non-
equivalent dependent variable [5] which would be
affected by all infection control interventions except the
MRSA universal screening. ITS analysis for both MRSA
and MSSA series was carried out, Q3, 2007 as the inter-
section between segments. The null hypothesis was that
changes in the positive blood cultures and positive
systemic samples other than blood cultures for MRSA
and the MSSA were similar.
We have included Durbin-Watson (DW) in the regres-
sions statistics to correct for possible auto-correlation.
DW value between 1.5 and 2.5 indicates that the values
are independent. All analysis was done using SPSS 19.
Results
Patients screened
The number of patients screened almost trebled from
1642 (3,432 specimens) in Q1, 2007 to 5087 (11,518
specimens) in Q2, 2007 then increased gradually over
the next quarters to finally stabilize over 15000
(40,000 specimens) by Q1, 2009 (Figure 2). The ratio
of patients to specimen numbers was about 1:2 in line
with the swabbing of nose (N) and throat (T) only.
However, this ratio has increased since Q2, 2008 to
just under 1:3 when we introduced inpatient MRSA
screening at every 10 days interval. The highest detec-
tion of on-admission prevalence of colonized patients
was achieved (3.59%) in the Q3, 2007 then sharply
reduced to 2%, Q2, 2008), 1%, Q3, 2010) and, finally,
dipped down to 0.89% in Q4, 2010 (R2 = 0.9), clearly
reflecting the efficacy of decolonization and successful
eradication (Figure 2).Estimation of baseline prevalence of MRSA colonization
The highest rate of MRSA positive systemic samples
(infections) other than blood cultures was 6.47% of
all admissions in Q1, 2005 which implies a rate of
colonization prevalence much higher than 6.47%. What
was the on-admission colonization rate could not be
extrapolated from inpatient infection burden but in Q1,
2007 the on-admission colonization detection rate was
only 1% with risk based targeted screening. The highest
on-admission detection rate of 3.59% was achieved in
Q3, 2007 after universal screening was commenced
(Figure 2). The impact of the universal screening and
decolonisation on the MRSA burden was immediate:
there was a sharp decline in on-admission colonisation
prevalence from a peak at 3.59% in Q3, 2007 to less
than 1% by Q4, 2010, while the number of patients
screened remained stable at just over 15,000/quarter.
These data reflect that detection by targeted screening
before the universal screening was by far less efficient.
Impact on MRSA bacteremias
The target set required a reduction from 67 to 27
bacteremias by April, 2008 equivalent to numbers falling
from 5.6 cases to 2.3 cases per month compared to the
baseline year. Initially, following the introduction of
RCA in May 2006, a tangible reduction in the numbers
was achieved on a month by month basis. A care path-
way for insertion, management and maintenance of cen-
tral and peripheral lines was introduced (November,
2006). However, in the subsequent months there was a
gradual increase with MRSA bacteremias peaking at 23
cases in Q2, 2007. The universal MRSA screening was
introduced in Q2, 2007 and an immediate and drastic
reduction in MRSA bacteremias was seen in Q3, 2007;
the declining trend continued till Q1, 2012 with only
two cases ≥48 h of hospitalization (hospital acquired) oc-
curring in 2011–12.
Visual inspection of data (Excel graphics) revealed an
immediate effect of universal screening in terms of sharp
decline of MRSA bacteremias as well as on positive
systemic (non-blood culture) samples in line with the
decline of MRSA on-admission prevalence.
There was an immediate sharp fall in all MRSA
bacteremias from 23, Q2 2007 to 10, Q3, 2007 followed
by a continued declining trend reaching zero Q4, 2010
(Figure 3). Predicted regression line showed a slight
decreasing trend in the slope before the intervention, an
abrupt drop in the rate immediately following the
intervention, and a gradually decreasing slope continued
after the intervention. The hospital acquired MRSA
bacteremias (≥48hours of hospitalization) dropped from 15
in Q2 2007 to 6 in Q3, 2007 followed by a continued de-

















































































































2003/2005 2004/2005 2005/2006 2006/2007 2007/2008 2008/2009 2009/2010 2010/2011 2011-2012
MRSA Pre MRSA Post MSSA Pre MSSA Post
Figure 3 MRSA and MSSA bacteraemias (all) pre- and post-universal screening.
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(ITS) analysis. The ITS analysis (Table 2) revealed
significant post-intervention drop of the baseline level of all
MRSA bacteremias, representing an immediate effect,
(β2 -0.554, p 0.000) and the post-intervention declining
trend (slope), representing a sustained effect (β3 -0.393,
p 0.048) where pre-intervention coefficient β1 was close to
0 (−0.033,) signifying a flat trend. The immediate effect was
equally prominent for hospital acquired MRSA bacteremias
i.e., ≥48 h of hospitalization (β2 -0.577, p 0.001) but
post-intervention slope was not statistically significant
(β2 -0.216, p 0.298) as the numbers were already very low
after the immediate sharp drop.
Impact estimation predicted 17 (all) and 13 (≥48 hours
of hospitalization) MRSA bacteremias, respectively in
the 19th quarter post-intervention if the intervention did
not occur, and, predicted zero bacteremias with inter-

























































2003/2005 2004/2005 2005/2006 2006/2007 2007/200
MRSA+48 Pre MRSA+48 Post
Figure 4 MRSA and MSSA1 bacteraemias ≥48 h of hospitalization preThere was no statistically significant impact of
universal screening on MSSA bacteremias. During the
whole observation period of 34 consecutive quarters
the number of MSSA bacteremias, both community
onset (R2 = 0.13) and ≥48 hours of hospitalization
(R2 = 0.09) have been declining slowly but not at a
statistically significant level (Figure 5, Table 2).
Impact on systemic Non-blood culture specimens
Similarly, there has been an equally significant impact
on the number of MRSA isolates from non-blood cul-
ture systemic sources: sterile fluid, tissues, respiratory
specimens and swabs, superficial and deep (Figure 6).
The number of positive specimens as percentage of
admissions dropped from 3.32% in Q2, 2007 to 1.51% in
Q3, 2007. The declining trend continued steadily over
the following quarters to the lowest 0.25% in Q4, 2010



















































8 2008/2009 2009/2010 2010/2011 2011-2012
MSSA 48+ Pre MSSA 48+ Post
- and post-universal screening.
Table 2 Interrupted time-series regression analysis of the MRSA/MSSA bacteremias (total and ≥48 h), MRSA/MSSA
systemic (Hospital - % of admissions) and MRSA/MSSA systemic (Community – total numbers)
Parameter Unstandardized Standardized t p 95% CI D-W
Coefficients - B (Std. Error) Coefficients - β
MRSA bacteremias Constant 17.40 (1.64) 10.59 .000 14.04 to 20.75 1.573
Pre-intervention trend -.025 (.181) -.033 -.138 .891 -.39 to .34
Post-intervention change −8.32 (2.072) -.554 −4.016 .000 −12.55 to −4.09
Post-intervention trend -.45 (.221) -.393 −2.065 .048 -.90 to -.005
MSSA bacteremias Constant 17.36 (2.45) 7.075 .000 12.35 to 22.37 2.068
Pre-intervention trend .29 (.270) .604 1.098 .281 -.255 to .848
Post-intervention change −2.28 (3.095) -.235 -.737 .467 −8.60 to 4.04
Post-intervention trend -.61 (.330) -.818 −1.858 .073 −1.28 to.06
MRSA ≥48 h bacteremias Constant 13.46 (1.38) 9.75 .000 10.64 to 16.28 1.753
Pre-intervention trend -.10 (.152) -.168 -.659 .515 -.41 to .21
Post-intervention change −6.79 (1.741) -.577 −3.901 .001 −10.34 to −3.23
Post-intervention trend -.19 (.185) -.216 −1.060 .298 -.57 to .18
MSSA ≥48 h bacteremias Constant 5.96 (1.84) 3.22 .003 2.16 to 9.76 1.901
Pre-intervention trend .173 (.272) .503 .634 .532 -.38 to .73
Post-intervention change 1.10 (2.112) .178 .521 .606 −3.24 to 5.44
Post-intervention trend -.45 (.298) -.990 −1.524 .140 −1.06 to .15
MRSA Systemic (Trust) Constant 5.8 (.225) 25.78 .000 5.34 to 6.26 1.599
Pre-intervention trend -.17 (.028) -.830 −6.252 .000 -.23 to -.11
Post-intervention change −2.03 (.271) -.506 −7.493 .000 −2.58 to −1.47
Post-intervention trend .10 (.033) .350 3.269 .003 .040 to 17
MSSA Systemic (Trust) Constant 3.25 (.191) 17.01 .000 2.86 to 3.64 1.421
Pre-intervention trend -.05 (.024) -.892 −2.358 .026 -.10 to -.007
Post-intervention change .29 (.230) .248 1.289 .208 -.17 to .76
Post-intervention trend .134 (.028) 1.477 4.846 .000 .07 to .19
MRSA Systemic (GP) Constant 287 (12.35) 23.25 .000 262 to 313 1.962
Pre-intervention trend −2.49 (1.55) -.285 −1.602 .120 −5.68 to .69
Post-intervention change −66.23 (14.89) -.402 −4.447 .000 −96.73 to −35.72
Post-intervention trend −4.22 (1.78) -.338 −2.362 .025 −7.88 to -.56
MSSA Systemic (GP) Constant 906 (31.57) 28.71 .000 841 to 971 2.427
Pre-intervention trend −7.52 (3.97) −1.27 −1.891 .069 −15.67 to .62
Post-intervention change 11.71 (38.04) .105 .308 .760 −66.22 to 89.65
Post-intervention trend 10.16 (4.56) 1.20 2.224 .034 .80 to 19.51
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sharp post-intervention drop representing an immedi-
ate effect (β2 -0.506, p 0.000). However, there was no
prominent post-intervention declining trend (β3 0.350,
p 0.003) as the rate already dropped and was running
at a very low level at < 0.3%. Percentage of MRSA of
all S. aureus isolates (non-blood culture systemic
sources) declined from 51% Q2, 2007 (peak was at
67.54% in Q3, 2005) through 34% Q3, 2007 to 8.7% in
Q1, 2012.
The immediate decline and post-intervention declin-
ing trend were also significant for MRSA non-blood
culture systemic specimens from general practitioners(GP): β2 -0.402, p 0.000; β3 -0.338, p 0.025 whereas
pre-intervention declining trend was not significant
(Table 2).
Of note, however, there was no concomitant reduction
in MSSA isolates from non-blood culture systemic
sources observed. Instead, there was a slow but statisti-
cally significant post-intervention increasing trend in the
rate of hospital MSSA (R2 = 7.3, Figure 7) confirmed by
ITS analysis (β3 1.477, p 0.000). The ITS analysis also
revealed post-intervention increasing trend in the num-
bers of non-blood culture systemic MSSA from GP
(β3 1.20, p 0.034) although the predicted regression line
was not significant (R2 = 0.06).
y = -0.1762x + 20.936
R2 = 0.1288
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Figure 5 MSSA bacteraemias trend pre- and post-universal screening.
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Each specimen was associated with a consumable cost of
£0.62 for a negative screen and, additional, £2.16 for a
positive specimen (identification and sensitivity). Esti-
mated cost of screening was £24,800 per quarter plus
£1080 based on the current quarterly positive number of
about 500. The yearly cost of universal screening was
just over £100,000 for laboratory consumables alone. In
Q1, 2012 a combined NP Elution Swab (ESwab) in
Liquid Amies medium was introduced reducing the
number of specimens to half. The Eswab costs £0.45
more compared to the standard Amies swab, so, total


























































2004/2005 2005/2006 2006/2007 2007/2008
Admissions (Total) MRSA-Trust (Pre
S. aureus (Trust) Linear (MRSA-Tru
Figure 6 Non-blood culture systemic MRSA vs. S. aureus (primary axis
Q4, 2002 to Q1, 2012.Mupirocin resistance
The resistance to mupirocin (hospital isolates) margin-
ally increased from 1.7% in 2004 to 2.3% in 2011.
Conclusion
In the era of multi-resistant pathogens, focusing hospital
resources on a single antibiotic-resistant pathogen as a
sole approach to infection control is criticized as inher-
ently flawed [6]. Questions were also raised regarding
the impact of universal screening on MRSA bacteremia
rate given the sensitivity of the screening, lack of isola-
tion rooms, the relatively low effectiveness of current
decolonization techniques, staffing time and financial
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Admissions (Total) MSSA-Trust (Pre Intervention) MSSA-Trust (Post Intervention) 
S. aureus (Trust) Linear (MSSA-Trust (Post Intervention) )
Figure 7 Non-blood culture systemic MSSA vs. S. aureus (primary axis) isolates with number of admissions (secondary axis) between
Q4, 2002 to Q,1 2012.
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more evidence before it becomes routine considering
resource requirements, practical difficulties and conse-
quences [7]. In hospitals with an MRSA on-admission
prevalence of < 5% targeted rather than universal screen-
ing is advocated [8].
In our study, all interventions were targeted at both
MRSA and MSSA except the screening and decolonization
but decline in MSSA bacteremias over the 34 consecutive
quarters of observation was not statistically significant,
which served as a natural control (non-equivalent
dependent variable) in the analysis. In contrast, a drastic
drop and quarterly declining trend in MRSA bacteremias
continued, reaching zero following the introduction of uni-
versal screening. In national context, during the first 2 years
following setting of the national target in November 2004,
there was minimal reduction; however, from September
2006 onwards, rates declined dramatically to reach a
reported 57% reduction by April–June 2008 [9-11]. In our
organization, dramatic decline in MRSA bacteremias and
systemic infections was clearly linked to the introduction of
universal screening and decolonization. This is consistent
with reports that widespread uptake of decolonization has
made the key additional contribution [11,12]. The effect of
hand hygiene, identification of patients with MRSA infec-
tions or colonization and isolation interventions alone leads
only to a gradual reduction in MRSA burden over many
years [13]. The Pathfinder project [14], an implementation
project to evaluate the impact of universal screening
recommended by the NHS QIS HTA modeling [15], also
found a temporal association between the initiation of uni-
versal screening and a significant reduction in colonization
from 5.5% to 3.5% by month 12. However, no significantreduction in the rate of MRSA bacteremias and Surgical
Site Infections (SSI) during the study was found. A
re-worked model using observed parameters from the
Pathfinder study projected that colonization prevalence
could reduce over three to five years to low endemic levels
(0.5-1.8%) with a chromogenic agar based universal screen-
ing strategy. Our study results support this projection.
In one neighbouring NHS Trust only seven additional
day case patients in one month period would have been
identified as MRSA carriers using the DoH universal
screening compared with their targeted approach [16].
However, this Trust had already embarked on an
expanded screening programme in three phases and
needed to extend the screening only to day cases and
elective admissions to comply with mandatory universal
screening commenced in April, 2009. It is only to be
expected that a successful screening and decolonization
programme over a period would eventually lower the
burden and a corresponding fall in MRSA detection
rate.
In previous studies fluoroquinolone restriction was
associated with decline in MRSA infections [17]. In our
study MRSA rates dropped during the period when
fluoroquinolone were used unrestricted albeit at a low
level of average 12 DDD/100 bed-days per month. Our
Fluroquinolone consumption more than halved to under
5 DDD/bed-days from June, 2008 which further dropped
to under 2 from June, 2010. This low level of consump-
tion may have positively impacted on our sustained low
burden of MRSA infections.
Once low on-admission prevalence has been consoli-
dated and sustained, a first line ‘risk assessment’ screen-
ing tool to reduce swabbing, laboratory costs and
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be preemptively isolated is a logical way forward. One
study found that a simple three question Clinical Risk
Assessment (CRA) could perform to a similar level to
universal single site swabbing, but with considerably
reduced resource implications [15]. The CRA has to be
based on the local MRSA epidemiology, infection con-
trol practices and vulnerability of the patient population.
The ITS methods used in this study have several
advantages over other quasi-experimental studies, be-
cause they are less likely to be influenced by certain
biases [18-20]. Cyclical effects and underlying increas-
ing or decreasing secular trends may contribute to
observed intervention effects. While looking at the
effect of specific intervention, the analysis has to take
into account the added effect of pre-existing or newly
introduced measures. Finally, auto-correlated data
means that adjacent data points can be more similar
(positive auto-correlation) or dissimilar (negative auto-
correlation), leading to under- or over-estimates of
effect, respectively. Unlike the classical statistical meth-
ods that assume the observed data are independent
random variables, time-series analysis takes into ac-
count the relationships existing between consecutive
observations, a phenomenon known as auto-correl-
ation. However, as with all non-experimental designs,
causal inference from ITS designs is limited because it
is impossible to rule out alternative explanations for
observed changes in the time series.
Our experience with the precipitous decline in the
burden of MRSA provides clear evidence of the efficacy
of universal screening and decolonization. We achieved
a very high level of compliance with screening uptake
and decolonization. However, this success has to be con-
sidered in the context of the highly empowered weekly
HCAI meeting in operation since May, 2007. This group
have been ensuring continued compliance to MRSA
screening, PVC care plan use and hand hygiene review-
ing weekly audits and feeding back to the relevant staff
with timely recommendation of appropriate measures
backed by the support from the management.
It is noteworthy that our success was in the back-
ground of a declining trend in MRSA infections in
England [11], the USA [21] and elsewhere during the
period. If there is an epidemiological explanation,
perhaps, an effect predicated on natural biological
trends involving specific MRSA strains is a matter of
great interest [11,22,23].
The study reveals one disturbing trend. The rate of
non-blood culture systemic MSSA positive samples from
the trust since Q2, 2007 is increasing. Also, the MSSA
bacteremia trend appears to be decreasing only slowly
and not at a significant level. This warrants specific
actions to combat the MSSA burden.Competing interests
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